Study to Evaluate the Efficacy and Safety of CKD-350

NCT02777723 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

138

Enrollment

INDUSTRY

Sponsor class

Conditions

Dry Eye Syndrome

Interventions

DRUG: Xenobella
DRUG: Isotonic 0.3% Sodium Hyaluronate

Sponsor

Chong Kun Dang Pharmaceutical